Ticagrelor Versus Clopidogrel in Acute Coronary Syndromes in Relation to Renal Function

Response to Ticagrelor in Clopidogrel Nonresponders and Responders and Effect of Switching Therapies

(2010) Paul A. Gurbel et al.   CIRCULATION

Comparison of ticagrelor, the first reversible oral P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial

(2009) Stefan James et al.   AMERICAN HEART JOURNAL

Ticagrelor: The First Reversibly Binding Oral P2Y12Receptor Antagonist

(2009) Steen Husted et al.   Cardiovascular Therapeutics

Baseline Risk of Major Bleeding in Non–ST-Segment–Elevation Myocardial Infarction

(2009) Sumeet Subherwal et al.   CIRCULATION

Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes

(2009) Lars Wallentin et al.   NEW ENGLAND JOURNAL OF MEDICINE

The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: Results from the Clopidogrel for the Reduction of Events During Observation (CREDO) Trial

(2008) Patricia J.M. Best et al.   AMERICAN HEART JOURNAL

Cockcroft-Gault Versus Modification of Diet in Renal Disease

(2008) Chiara Melloni et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY